This trial is evaluating whether CY6463 will improve 1 primary outcome in patients with Alzheimer Disease. Measurement will happen over the course of From first dose of study treatment through ~14 (±4) days after the final dose.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. CY6463 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
The brain can be regenerated to a certain degree, but the brain is not and cannot be regenerated to full functioning status in humans with Alzheimer's.\n
Anti-cholinergic medications like antipsychotic and antihistamine medications and hypnotics like benzodiazepines/barbiturates were all highly prescribed. Use of antiemetics by physicians was also commonplace, but they were rarely prescribed by themselves.
Based on information from the Alzheimer Disease and Associated Disorders Information system (ADARIS), Alzheimer disease currently affects approximately 4 million Americans each year. Most people will get dementia before age 80, but many have at least a few years where their memory and cognitive abilities are unimpaired.
The most frequently found causes of AD are genetics; environmental hazards; and some drugs. The causes of AD are not yet fully understood. More work on genetics in AD and in finding causes may help to understand the disease process.
Symptoms of AD include the following: dementia with cognitive dysfunction and behavioral problems; visual hallucinations (especially in Alzheimer's disease); paranoia; mood and sleep disorders; memory or cognitive impairments; and difficulty with thinking and communicating.\n
It is a disease that causes significant brain deterioration and progressive cognitive impairment, and it was found that the incidence of the disease increased as the level of education increased up to 7 years, and it was found that the risk of occurrence increased by 3 in every 2,000 women who did not have the disease and who started life at a younger age.
Recent findings provides the first reported clinical pharmacokinetics of cy6463 after oral administration in a community setting. The mean area under the concentration-time curve was similar to that from studies in healthy volunteers. Cy6463 is well tolerated in people with moderate to severe cognitive impairment; however, further studies are needed that assess the safety and efficacy of this new compound, especially in people with dementia.
Recent studies show that brain stimulation may have beneficial effects for Alzheimer's patients. In addition, evidence shows that low-level laser therapy is useful for alleviating several symptoms for dementia patients.
There have not been any other clinical trials investigating the effect of cy6463 which have been published in peer-reviewed journals since 2013. However, [UCLA study, above] has shown a number of favorable outcomes when comparing cy6463 with placebo. In addition, there are no known side effects or side effects in relation to the drug which could lead to a drug interaction. Thus, cy6463 is likely safe to use and has the probability to be a highly effective treatment option in patients with Alzheimer's disease.
Patients are seeking help for memory problems, often from a neurologist. Patients are also looking for interventions to ease their memory and emotional difficulties. However, while more research continues, the evidence base for treating and preventing Alzheimer disease may continue to be sparse and uncertain.
This small case series did not confirm previous claims, that cy-6464 appears to be more effective than a placebo for moderate-severe Alzheimer's disease. However, patients can benefit from therapy, or be harmed, through unwanted side effects. Cy-6464 treatment should only be used under the supervision of a professional.
There are many factors and individual histories that determine when a person will develop Alzheimer disease, including age at onset. Since it is believed that the genes involved in Alzheimer disease change over the life of an individual, one cannot pinpoint exactly the age at which Alzheimer will begin to develop. The most common time to get Alzheimer's is in your 70s. It is imperative for people to be proactive in their health and start [doing things like eating a healthy diet], working on their brain, [doing things like exercising regularly] and getting screened for early Alzheimer's by your doctor. While the outlook for those who are diagnosed with Alzheimer's is [always poor, because it is a disease with a 100% mortality rate (i.e.